Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy

Torre, 2015, Global Cancer Statistics, 2012, CA Cancer J Clin, 65, 87, 10.3322/caac.21262 Langendijk, 2008, Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy, J Clin Oncol, 26, 3770, 10.1200/JCO.2007.14.6647 Romesser, 2016, Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation, Radiother Oncol, 118, 286, 10.1016/j.radonc.2015.12.008 De Felice, 2018, Radiotherapy controversies and prospective in head and neck cancer: a literature-based critical review, Neoplasia (United States), 20, 227, 10.1016/j.neo.2018.01.002 Gunn, 2016, Clinical outcomes and patterns of disease recurrence after intensity modulated proton therapy for oropharyngeal squamous carcinoma, Int J Radiat Oncol Biol Phys, 95, 360, 10.1016/j.ijrobp.2016.02.021 Zhang, 2017, Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer, Radiother Oncol, 123, 401, 10.1016/j.radonc.2017.05.006 Blanchard, 2016, Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer – a case matched analysis, Radiother Oncol, 120, 48, 10.1016/j.radonc.2016.05.022 Mohamed, 2017, Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions, Radiother Oncol, 124, 248, 10.1016/j.radonc.2017.07.017 De Felice, 2015, Analysis of loco-regional failures in head and neck cancer after radical radiation therapy, Oral Oncol, 51, 1051, 10.1016/j.oraloncology.2015.08.004 Salama, 2007, Chemoradiotherapy for locally advanced head and neck cancer, J Clin Oncol, 25, 4118, 10.1200/JCO.2007.12.2697 Lefebvre, 2012, Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891, Ann Oncol, 23, 2708, 10.1093/annonc/mds065 Vignoud, 2004, Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas, Laryngoscope, 107, 648 Madani, 2011, Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer q, Radiother Oncol, 101, 351, 10.1016/j.radonc.2011.06.020 Bourhis, 2006, Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis, Lancet, 368, 843, 10.1016/S0140-6736(06)69121-6 Horiot, 1992, Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy, Radiother Oncol, 25, 231, 10.1016/0167-8140(92)90242-M Fellman, 2015, Bayesian optimal interval design for phase I oncology clinical trials, Stata J, 15, 110, 10.1177/1536867X1501500107 Olteanu, 2018, Late mucosal ulcers in dose-escalated adaptive dose-painting treatments for head-and-neck cancer, Acta Oncol (Madr), 57, 262, 10.1080/0284186X.2017.1364867 Marzi, 2012, Anatomical and dose changes of gross tumour volume and parotid glands for head and neck cancer patients during intensity-modulated radiotherapy: effect on the probability of xerostomia incidence, Clin Oncol (R Coll Radiol), 24, e54, 10.1016/j.clon.2011.11.006 Cheung, 2000, Sequential designs for phase I clinical trials with late-onset toxicities, Biometrics, 56, 1177, 10.1111/j.0006-341X.2000.01177.x Madani, 2011, Maximum tolerated dose in a phase i trial on adaptive dose painting by numbers for head and neck cancer, Radiother Oncol, 101, 351, 10.1016/j.radonc.2011.06.020 Forastiere, 2003, Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer, N Engl J Med, 349, 2091, 10.1056/NEJMoa031317 Hitt, 2005, Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer, J Clin Oncol, 23, 8636, 10.1200/JCO.2004.00.1990 Hitt, 2014, A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer, Ann Oncol, 25, 216, 10.1093/annonc/mdt461 Nguyen-Tan, 2014, Randomized phase III Trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity, J Clin Oncol, 32, 3858, 10.1200/JCO.2014.55.3925 Magrini, 2016, Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial, J Clin Oncol, 34, 427, 10.1200/JCO.2015.63.1671 Ghi, 2017, Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial, Ann Oncol, 28, 2206, 10.1093/annonc/mdx299 Noronha, 2018, Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial, J Clin Oncol, 36, 1064, 10.1200/JCO.2017.74.9457 Tao, 2018, Improved outcome by adding concurrent chemotherapy to cetuximab and radiotherapy for locally advanced head and neck carcinomas: results of the GORTEC 2007–01 phase III randomized trial, J Clin Oncol, 36, 3084, 10.1200/JCO.2017.76.2518 Geoffrois, 2018, Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: Results of the GORTEC 2007–02 Phase III Randomized Trial, J Clin Oncol, 36, 3077, 10.1200/JCO.2017.76.2591 Gillison, 2019, Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial, Lancet, 393, 40, 10.1016/S0140-6736(18)32779-X Cohen, 2014, Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer, J Clin Oncol, 32, 2735, 10.1200/JCO.2013.54.6309 Lomax, 2009, Charged particle therapy: the physics of interaction, Cancer J, 15, 285, 10.1097/PPO.0b013e3181af5cc7 Water, 2011, The potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: a systematic review of literature, Oncologist, 16, 366, 10.1634/theoncologist.2010-0171 Shune, 2012, Association between severity of dysphagia and survival in patients with head and neck cancer, Head Neck, 34, 776, 10.1002/hed.21819 Bradley, 2015, Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p, Lancet Oncol, 16, 187, 10.1016/S1470-2045(14)71207-0 Cramer, 2018, Validation of the eighth edition American Joint Committee on Cancer staging system for human papillomavirus-associated oropharyngeal cancer, Head Neck, 40, 457, 10.1002/hed.24974 Ang, 2010, Human papillomavirus and survival of patients with oropharyngeal cancer, N Engl J Med, 363, 24, 10.1056/NEJMoa0912217 Aerts, 2014, Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach, Nat Commun, 5 Vallières, 2015, A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities, Phys Med Biol, 60, 5471, 10.1088/0031-9155/60/14/5471 Zhai, 2017, Improving the prediction of overall survival for head and neck cancer patients using image biomarkers in combination with clinical parameters, Radiother Oncol, 124, 256, 10.1016/j.radonc.2017.07.013 Zhai, 2018, Prognostic value of CT-based image-biomarkers for treatment outcomes of head and neck cancer patients, Int J Radiat Oncol Biol Phys Kumar, 2012, Radiomics: the process and the challenges, Magn Reson Imaging, 30, 1234, 10.1016/j.mri.2012.06.010